Materials and methods for treatment of inflammatory and cell proliferation disorders

• US 8,148,114 B2
• Filed: 10/27/2008
• Issued: 04/03/2012
• Est. Priority Date: 02/17/2004
• Status: Expired due to Fees

• Current Assignee: University of South Florida (State University System of Florida)
• Original Assignee: University of South Florida (State University System of Florida)
• Inventors: Mohapatra, Shyam S
• Primary Examiner(s): Ha, Julie
• Application Number:
  US12/259,110
• Publication Number:
  US 20090176706A1
• Time in Patent Office: 1,254 Days
• Field of Search: None
• US Class Current: 435/91.1
• CPC Class Codes: A61K 38/2242 Atrial natriuretic factor complex: Atriopeptins, atrial natriuretic protein [ANP]; Cardionatrin, Cardiodilatin
• CPC Class Codes: A61K 48/0008 characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
• CPC Class Codes: A61K 48/005 characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: G01N 2500/04 Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
• CPC Class Codes: G01N 2500/10 involving cells

Abstract

Compositions and methods for treatment of inflammatory and cell proliferation disorders using natriuretic hormone peptide (NP), polynucleotides encoding NP, or agents that reduce the activity of atrial natriuretic peptide receptor A (NPR-A).

Claims

1. A method of inhibiting the growth of cancer cells in a patient, comprising administering a polynucleotide encoding a natriuretic hormone peptide (NP) and an operably-linked promoter sequence, to the patient, wherein the cancer cells comprise lung cancer cells, breast cancer cells, ovarian cancer cells, or melanoma cells.

2. The method of claim 1, wherein the NP comprises the amino acid sequence of SEQ ID NO:

5 or a homolog of SEQ ID NO;

5 having at least one conservative amino acid substitution of SEQ ID NO;

5.

3. The method of claim 1, wherein said administering is by a route selected from the group consisting of oral, intramuscular, parenteral, intravenous, and intranasal.

4. The method of claim 1, wherein the polynucleotide is administered with a pharmaceutically acceptable carrier.

5. The method of claim 1, wherein the polynucleotide is contained within an expression vector.

6. The method of claim 5, wherein the expression vector is a DNA plasmid or virus.

7. The method of claim 1, wherein the polynucleotide sequence is administered with chitosan.

8. The method of claim 1, wherein the patient is suffering from one or more tumors, and wherein the NP causes regression of one or more of the tumors in the patient.

9. The method of claim 1, wherein the NP reduces tumor growth and metastasis in the patient.

10. The method of claim 1, wherein the patient is human.

11. The method of claim 1, wherein the cancer cells comprise lung cancer cells, and wherein the polynucleotide is administered to the airways of the patient.

12. The method of claim 2, wherein the cancer cells comprise lung cancer cells, and wherein the polynucleotide is administered to the airways of the patient.

13. The method of claim 12, wherein the patient is suffering from one or more tumors, and wherein the NP causes regression of one or more of the tumors in the patient.

14. The method of claim 1, wherein the NP comprises the amino acid sequence of SEQ ID NO:

5.

15. The method of claim 1, wherein the cancer cells comprise breast cancer cells.

16. The method of claim 2, wherein the cancer cells comprise breast cancer cells.

17. The method of claim 1, wherein the cancer cells comprise ovarian cancer cells.

18. The method of claim 2, wherein the cancer cells comprise ovarian cancer cells.

19. The method of claim 1, wherein the cancer cells comprise melanoma cells.

20. The method of claim 2, wherein the cancer cells comprise melanoma cells.